The new microchip biological 1.1 drug xidaban (epsiloxane) has been approved by CFDA for marketing

Cidabamide belongs to a new mechanism of action - epigenetic regulators of anti-tumor drugs CFDA approved it for the treatment of relapsed and refractory peripheral T-cell lymphoma Peripheral T-cell lymphoma (PTCL) is a group of highly heterogeneous lymphoproliferative disorders, including 23 pathological subtypes The distribution of PTCL subtypes in different regions is different In North America and Europe, PTCL is not the most common type (PTCL-NOS), and the incidence rate is high in China, including extranodal NK/T cell lymphoma and angioimmunocyte lymphoma At present, there is a lack of recommended treatment of standard drugs in clinical practice The response rate to conventional chemotherapy is low and easy to relapse The 5-year overall survival rate is only 25-30% There is no special medicine for this kind of disease in China, which is an urgent clinical demand The clinical trial of sidabamide combined with other anti-tumor drugs in the treatment of non-small cell lung cancer and recurrent and metastatic breast cancer is in progress It took 12 years from the discovery to the approval of xidaban, which is a special subject of "863", "11th Five Year Plan" and "12th Five Year Plan" of China Sidabamide (epsiloxane ®) sidabamide is a selective inhibitor of benzamide HDAC subtype It has a re regulation effect on the epigenetic abnormality of tumorigenesis for subtypes 1, 2, 3 and 10 of type IIB in HDAC type I Sidababamine can induce chromatin remodeling by inhibiting the HDAC subtype to increase the acetylation level of histone, and thus produce gene expression changes (i.e epigenetic changes) of multiple signaling pathways for tumor development Xidabamide can directly inhibit the cell cycle and induce apoptosis of tumor cells in the blood and lymphoid system, induce and activate natural killer cells (NK) and antigen-specific cytotoxic T The cytotoxic effect of CTL can regulate the immunity of anti-tumor cells as a whole; xidaban can also induce the differentiation of tumor stem cells and reverse the epithelial mesenchymal phenotype transformation (EMT) of tumor cells through epigenetic regulation mechanism, so as to restore the sensitivity of drug-resistant tumor cells to drugs and inhibit tumor metastasis and recurrence Potential effects Xidabamide has completed the clinical research of peripheral T-cell lymphoma and cutaneous T-cell lymphoma, and the clinical trial of combined with other tumor drugs to treat solid tumors such as lung cancer and breast cancer is in progress At the same time, many clinical trials of xidabamide have also been carried out in the United States, Japan and Taiwan Bay Founded in 2001 by a senior returned home team in the United States, Shenzhen micro core bio is a leading enterprise in the field of biomedicine in China, specializing in the research and development of original small molecule drugs, with a team specialized in the technology, management and intellectual property rights of original new drugs, and with complete capabilities from drug target research to clinical development and industrialization of new drugs With the core competitiveness of "integrated drug discovery and early evaluation platform based on chemical genomics" and the goal of "original, safe and effective", microchip is committed to providing patients with affordable innovative mechanism therapy drugs Many breakthroughs have been made in the development of innovative small molecule drugs for major diseases, with global patent protection and unique clinical effects As one of the first batch of "innovative drug incubation bases" for major national science and technology projects, microchip biology independently undertook a number of national "863" and "major new drug creation" science and technology projects, and won the first prize of national science and Technology Progress Award in 2013 Products and product lines